Skip to main content
Top
Published in: Supportive Care in Cancer 12/2020

01-12-2020 | Insomnia | Original Article

A randomized phase II trial evaluating two non-pharmacologic interventions in cancer survivors for the treatment of sleep-wake disturbances: NCCTG N07C4 (Alliance)

Authors: Debra L. Barton, Pamela J. Atherton, Daniel V. Satele, Rui Qin, Shaker Dakhil, Teri Pipe, Timothy Hobday, Kelli Fee-Schroeder, Charles L. Loprinzi

Published in: Supportive Care in Cancer | Issue 12/2020

Login to get access

Abstract

Purpose

Sleep disturbance is a prevalent problem for cancer survivors and effective behavioral treatments are not widely used for this population. This study evaluated home-based sleep interventions based on cognitive behavioral therapy for insomnia (CBT-I).

Methods

This phase II randomized controlled trial evaluated two manualized interventions over 7 weeks. The intervention group received sleep hygiene information, stimulus control, sleep restriction, and a bedtime imagery audio recording. The control group was similar, but without sleep restriction and used audio recordings of bedtime short stories instead of imagery. Eligibility included adult cancer survivors who had trouble falling asleep or falling back to sleep on 3 of 7 days. Patients with diagnoses of sleep or mental health disorders were excluded. The primary endpoint was change in time to fall asleep or falling back to sleep after awakening, from baseline to week 7. Two-sample T tests evaluated differences between arms for this endpoint.

Results

Ninety-three of 168 planned participants were enrolled from 20 institutions. The study closed early for poor accrual. Baseline time to sleep was 45 min and 52 min for the intervention and control group, respectively. At 7 weeks, both groups improved, the intervention group to 26 min and control group to 30 min, a non-significant difference between groups (p = 0.85). Secondary outcomes improved in both groups with no significant differences between arms.

Conclusions

Improvement in sleep outcomes in both arms was consistent with other CBT-I interventions delivered through alternative approaches to provider-delivered therapy. More research on optimal scalable delivery of CBT-I is needed.

Clinical relevance

This study supports the effectiveness of CBT-I based behavioral interventions for sleep but also the need for better delivery methods to improve uptake and effect size.

Trial registration

ClinicalTrials.​gov identifier: NCT00993928
Literature
9.
go back to reference Ishak WW, Bagot K, Thomas S, Magakian N, Bedwani D, Larson D, Brownstein A, Zaky C (2012) Quality of life in patients suffering from insomnia. Innov Clin Neurosci 9:13–26PubMedPubMedCentral Ishak WW, Bagot K, Thomas S, Magakian N, Bedwani D, Larson D, Brownstein A, Zaky C (2012) Quality of life in patients suffering from insomnia. Innov Clin Neurosci 9:13–26PubMedPubMedCentral
11.
go back to reference Morin CM, Culbert JP, Schwartz SM (1994) Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry 151:1172–1180CrossRef Morin CM, Culbert JP, Schwartz SM (1994) Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry 151:1172–1180CrossRef
24.
go back to reference Naparstek B (2000) A guided meditation for healthful sleep [audio recording]. (Available from Health Journeys, 3615 Superior Avenue, Suite 4403D, Cleveland, OH, 44114 or healthjourneys.com) Naparstek B (2000) A guided meditation for healthful sleep [audio recording]. (Available from Health Journeys, 3615 Superior Avenue, Suite 4403D, Cleveland, OH, 44114 or healthjourneys.​com)
27.
go back to reference Owen DC, Parker KP, McGuire DB (1999) Comparison of subjective sleep quality in patients with cancer and healthy subjects. Oncol Nurs Forum 26:1649–1651PubMed Owen DC, Parker KP, McGuire DB (1999) Comparison of subjective sleep quality in patients with cancer and healthy subjects. Oncol Nurs Forum 26:1649–1651PubMed
29.
go back to reference McNair DM, Loor M, Dropplean LF (1993) Profile of mood states manual. Multi-Health Systems, New York McNair DM, Loor M, Dropplean LF (1993) Profile of mood states manual. Multi-Health Systems, New York
41.
42.
go back to reference Guthrie KA, Larson JC, Ensrud KE, Anderson GL, Carpenter JS, Freeman EW, Joffe H, LaCroix AZ, Manson JE, Morin CM, Newton KM, Otte J, Reed SD, McCurry SM (2018) Effects of pharmacologic and nonpharmacologic interventions on insomnia symptoms and self-reported sleep quality in women with hot flashes: a pooled analysis of individual participant data from four MsFLASH trials. Sleep 41:zsx190. https://doi.org/10.1093/sleep/zsx190CrossRefPubMedCentral Guthrie KA, Larson JC, Ensrud KE, Anderson GL, Carpenter JS, Freeman EW, Joffe H, LaCroix AZ, Manson JE, Morin CM, Newton KM, Otte J, Reed SD, McCurry SM (2018) Effects of pharmacologic and nonpharmacologic interventions on insomnia symptoms and self-reported sleep quality in women with hot flashes: a pooled analysis of individual participant data from four MsFLASH trials. Sleep 41:zsx190. https://​doi.​org/​10.​1093/​sleep/​zsx190CrossRefPubMedCentral
Metadata
Title
A randomized phase II trial evaluating two non-pharmacologic interventions in cancer survivors for the treatment of sleep-wake disturbances: NCCTG N07C4 (Alliance)
Authors
Debra L. Barton
Pamela J. Atherton
Daniel V. Satele
Rui Qin
Shaker Dakhil
Teri Pipe
Timothy Hobday
Kelli Fee-Schroeder
Charles L. Loprinzi
Publication date
01-12-2020
Publisher
Springer Berlin Heidelberg
Keyword
Insomnia
Published in
Supportive Care in Cancer / Issue 12/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-020-05461-6

Other articles of this Issue 12/2020

Supportive Care in Cancer 12/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine